Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers

Executive Summary

Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.

Advertisement

Related Content

Five Prime/Inhibrx Deal Has First ‘Breakthrough’ Milestone Payments
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split
Breakthrough Therapies: FDA Not Writing A Scientific Guidance – Yet
Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes
Industry Wants A Breakthrough Therapy, Even Without All The Standards
FDA To Provide Expedited Approval Desktop Reference
Xalkori And The Art Of Modern Drug Development
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel